https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg
** UCB to license its AI technology that improves identification of Osteopo=
rosis to ImageBiopsy Lab
------------------------------------------------------------
=C2=B7 ImageBiopsy Lab will further develop and launch an AI-based fracture=
identification tool based on UCB-developed BoneBot AI technology which det=
ects the presence of =E2=80=9Csilent=E2=80=9D or asymptomatic fractures in =
the spine through the use of artificial intelligence (AI).=C2=A0
=C2=B7 Currently more than two-thirds of vertebral fractures are undiagnose=
d. Identifying them systematically has proven to be challenging for all cli=
nicians.
=C2=B7 ImageBiopsy Lab will integrate UCB=E2=80=99s BoneBot technology with=
its existing ImageBiopsy Lab ZOO MSK platform for delivery to hospitals to=
help to increase the reporting of spinal fractures, enabling diagnosis and=
treatment earlier in the treatment journey, potentially reducing the co-mo=
rbidities associated with osteoporosis.
=C2=B7 UCB=E2=80=99s licensing of BoneBot AI technology to ImageBiopsy Lab =
to improve time to market demonstrates UCB=E2=80=99s ongoing commitment to =
a world free of fragility fractures.
Brussels (Belgium), 20 October, 07:00 CET UCB today =E2=80=93 on World Oste=
oporosis Day 2021 =E2=80=93 announced a strategic out-licensing of Artifici=
al Intelligence (AI) based fracture identification technology, BoneBot, to =
ImageBiopsy Lab to bring the new identification tool to clinical practice b=
y 2023. The radiology AI solution will screen CT scans to detect the presen=
ce of =E2=80=9Csilent=E2=80=9D or asymptomatic fractures in the spine which=
can otherwise go unrecognized and unreported.=C2=A0
=E2=80=9CAs digitalization of health increases, so does the potential of le=
veraging AI for improving care for many diseases, including osteoporosis. T=
he number one risk factor for fragility fractures is a previous fracture. I=
dentifying and appropriately treating patients who have already suffered a =
vertebral fracture is therefore key to ensuring that patients can continue =
to live their life to the fullest and avoid further fracture=E2=80=9D, said=
Emmanuel Caeymaex, Executive Vice President Immunology Solutions & Head of=
US at UCB. =E2=80=9CTogether with expert clinicians, UCB has developed a d=
eep-learning computational model that can detect vertebral compression frac=
tures on CT scans. Partnering with a leading musculoskeletal (MSK) radiolog=
y AI company will ensure this technology can be integrated into clinical ca=
re.=E2=80=9D=C2=A0
=E2=80=9CIt is our ambition to support the more than 9 million patients wor=
ldwide who suffer a fragility fracture due to osteoporosis each year by hel=
ping to identify those patients at highest risk. Strategic partnerships and=
investment with those who have the technology and data capabilities can dr=
ive our transformation further in the most impactful ways. We=E2=80=99re de=
lighted to be working with ImageBiopsy Lab to launch this important technol=
ogy.=E2=80=9D
Osteoporosis affects approximately 200 million people globally^1, resulting=
in 9 million fragility fractures each year with the most common type being=
vertebral fractures.^2,3
=E2=80=9CThe under-reporting in CT scans and consequent under-treating of v=
ertebral fractures remains a real challenge in health systems across the wo=
rld but this can be improved by a standard classification and a clearer pat=
h of care,=E2=80=9D said Bo Abrahamsen, Endocrinologist and Professor of Mu=
sculoskeletal Epidemiology. =E2=80=9CAlthough CT scans done for other purpo=
ses have the potential to identify vertebral fractures, scans containing ve=
rtebral fractures are often not assessed with this in mind, given the high =
time pressures on radiologists. There has to be a fast, simple, and intuiti=
ve way for vertebral fractures to be detected and brought to the attention =
of the services responsible for osteoporosis assessments. At the moment, th=
ese fractures are hiding in plain sight. We welcome digital innovation whic=
h can enable us to deliver clinical intervention earlier, ensuring patients=
receive the care they need.=E2=80=9D
Founded in 2016, ImageBiopsy Lab has become a leading musculoskeletal AI-su=
pported imaging diagnostic company. UCB will license the BoneBot Intellectu=
al Property (IP) to ImageBiopsy Lab, helping to bring the technology to mar=
ket by 2023. ImageBiopsy Lab will then aim to launch across the globe, incl=
uding the US, EU and UK.=C2=A0
=E2=80=9COn World Osteoporosis Day, when we work together to raise global a=
wareness of the prevention, diagnosis and treatment of osteoporosis, we=E2=
=80=99re excited to be announcing our involvement in such a significant mil=
estone for osteoporosis care,=E2=80=9D said Richard Ljuhar, CEO of ImageBio=
psy Lab. =E2=80=9CWe are looking forward to accelerating the time to impact=
of the BoneBot technology which will enable effective clinical interventio=
n earlier and, in turn, could potentially help reduce the co-morbidities as=
sociated with osteoporosis.=E2=80=9D
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With more than 8 000 people op=
erating in more than 40 countries, the company generated revenue of =E2=82=
=AC5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). F=
ollow us on Twitter: @UCB_news
About ImageBiopsy Lab=C2=A0
ImageBiopsy Lab, the Vienna-based MSK AI-solution developer, was founded as=
a spin-off in late 2016. The company develops and offers award-winning AI-=
driven software applications that digitize musculoskeletal (MSK) diagnostic=
s on radiographs, providing radiologists and orthopedics with fast, quantit=
ative and standardized reports of disease relevant findings and measurement=
s.=C2=A0
Today, ImageBiopsy Lab has offices in the EU and the US and brings together=
an interdisciplinary, international team of physicians, clinical researche=
rs and software experts, sharing the passion for having a lasting and meani=
ngful impact on digital healthcare.
Forward looking statements =E2=80=93 UCB
This press release contains forward-looking statements based on current pla=
ns, estimates and beliefs of management. All statements, other than stateme=
nts of historical fact, are statements that could be deemed forward-looking=
statements, including estimates of revenues, operating margins, capital ex=
penditures, cash, other financial information, expected legal, political, r=
egulatory or clinical results and other such estimates and results. By thei=
r nature, such forward-looking statements are not guarantees of future perf=
ormance and are subject to risks, uncertainties and assumptions which could=
cause actual results to differ materially from those that may be implied b=
y such forward-looking statements contained in this press release. Importan=
t factors that could result in such differences include: changes in general=
economic, business and competitive conditions, the inability to obtain nec=
essary regulatory approvals or to obtain them on acceptable terms, costs as=
sociated with research and development, changes in the prospects for produc=
ts in the pipeline or under development by UCB, effects of future judicial =
decisions or governmental investigations, product liability claims, challen=
ges to patent protection for products or product candidates, changes in law=
s or regulations, exchange rate fluctuations, changes or uncertainties in t=
ax laws or the administration of such laws and hiring and retention of its =
employees.=C2=A0
UCB is providing this information as of the date of this press release and =
expressly disclaims any duty to update any information contained in this pr=
ess release, either to confirm the actual results or to report a change in =
its expectations. There is no guarantee that new product candidates in the =
pipeline will progress to product approval or that new indications for exis=
ting products will be developed and approved. Products or potential product=
s which are the subject of partnerships, joint ventures or licensing collab=
orations may be subject to differences between the partners. Also, UCB or o=
thers could discover safety, side effects or manufacturing problems with it=
s products after they are marketed. Moreover, sales may be impacted by inte=
rnational and domestic trends toward managed care and health care cost cont=
ainment and the reimbursement policies imposed by third-party payers as wel=
l as legislation affecting biopharmaceutical pricing and reimbursement.
For further information:=C2=A0
Media=C2=A0
Adriaan Snauwaert=C2=A0
Global Communications Manager, UCB=C2=A0
T: +32 497 70 23 46. Adriaan.Snauwaert@ucb.com=C2=A0
Investor Relations
Antje Witte,=C2=A0
Investor Relations, UCB=C2=A0
T+32 2 559 9414, antje.witte@ucb.com
REFERENCES
1. Reginster JY, Burlet N. Osteoporosis: A still increasing prevalence. Bon=
e. 2006;38(2 Suppl 1):S4=E2=80=939
2. Str=C3=B6m O, Borgstr=C3=B6m F, Kanis JA, et al. Osteoporosis: burden, h=
ealth care provision and opportunities in the EU: a report prepared in coll=
aboration with the International Osteoporosis Foundation (IOF) and the Euro=
pean Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteo=
poros. 2011;6:59=E2=80=93155. doi: 10.1007/s11657-011-0060-1
3. Warriner AH, Patkar NM, Curtis JR, et al. Which fractures are most attri=
butable to osteoporosis?. J Clin Epidemiol. 2011;64(1):46-53. doi:10.1016/j=
.jclinepi.2010.07.007
GenericFile
IBL - UCB Press Release - FINAL (https://mb.cision.com/Public/18595/3436309=
/b744d827fb1d35de.pdf)
______________________
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x85929x1x6868579x24000=
x6&Email=3Dregnews%40symexglobal.com.
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium
26/04/2024 20:00
25/04/2024 18:00
25/04/2024 07:01
23/04/2024 20:00
22/04/2024 07:01
19/04/2024 20:00
17/04/2024 07:01
12/04/2024 20:00
12/04/2024 18:01
12/04/2024 07:01